Test Price
2,800 AED✅ Home Collection Available
MYH7 Gene Cardiomyopathy, Familial Hypertrophic Type 1 Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
This advanced next‑generation sequencing assay delivers a definitive molecular diagnosis for familial hypertrophic cardiomyopathy type 1 with 99.9% diagnostic sensitivity, processed in our ISO 9001:2015 accredited laboratory under the supervision of a Consultant Medical Genetics specialist.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — Available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post-test result interpretation from our DHA-licensed Consultant Medical Genetics.
- Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This next‑generation sequencing (NGS) test screens the entire MYH7 gene for pathogenic variants linked to familial hypertrophic cardiomyopathy type 1, delivering a comprehensive molecular diagnosis in 3 to 4 weeks. The assay includes full gene coverage with copy number variant detection, enabling precise risk stratification and cascade screening for at‑risk family members.
| Feature | Our MYH7 NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Full gene coverage with copy number variant detection | Limited to known hotspots, may miss large deletions |
| Methodology | NGS (Next‑Generation Sequencing) – high throughput, clinically validated | Sanger sequencing – lower throughput, gene‑by‑gene approach |
| Turnaround Time | 3 to 4 weeks | 6–8 weeks |
| Cost | 2800 AED | Often > 3500 AED with limited scope |
Physician Insight & Safety Protocols
“The MYH7 gene is one of the most frequently implicated genes in familial hypertrophic cardiomyopathy. Comprehensive NGS analysis provides the granularity needed to distinguish pathogenic variants from benign polymorphisms, which is essential for accurate family counselling and clinical decision‑making. Every result is correlated with the patient’s echocardiographic and family history before a final interpretation is issued.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Notes on Test Utility
Exclusion Criteria
Patients unable to provide informed consent; minors without legal guardian authorization and a completed genetic counselling waiver; individuals unwilling to undergo mandatory pre‑ and post‑test genetic counselling sessions.
Emergency Red Flags
If you experience sudden chest pain, syncope, profound dyspnoea, or palpitations, seek immediate care at the nearest emergency department — do not postpone treatment while awaiting genetic results.
Patient FAQ & Clinical Guidance
1. What is the clinical value of MYH7 NGS testing for hypertrophic cardiomyopathy?
This test identifies the exact DNA variant responsible for your cardiomyopathy, enabling precise risk stratification, tailored surveillance intervals, and cascade screening of first‑degree relatives.
2. How is the sample collected and what is the turnaround time?
A certified phlebotomist collects a peripheral blood sample at your home using temperature‑controlled cold‑chain logistics. Results are reported within 3 to 4 weeks from sample receipt at the laboratory.
3. Will my insurance cover this test and how is my data protected?
We verify your insurance coverage directly via WhatsApp prior to collection. All genetic data is handled in compliance with UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 on health ICT security.
4. Do I need genetic counselling before and after the test?
Yes, mandatory pre‑test and post‑test genetic counselling sessions are provided by our DHA‑licensed Consultant Medical Genetics to ensure informed consent and accurate result comprehension.
UAE Regulatory & Data Privacy Adherence
Data Privacy Framework: This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
All genetic data is encrypted, access‑controlled, and stored within UAE‑based servers. Results are disclosed only to the ordering physician and the patient following verified identity protocols.
Clinical & Logistical Metadata
| Test Name | MYH7 Gene Cardiomyopathy, Familial Hypertrophic Type 1 Genetic Test |
| Price (AED) | 2800 |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Whole Blood (Peripheral) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full gene coverage with CNV detection |
| ICD-10-CM Code | I42.1 (Hypertrophic cardiomyopathy) |
| LOINC Code | 94246-7 (MYH7 gene full sequencing) |
| DHA Facility License & Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians